Laurent Gbagbo ce mardi à Cocody (Ph KOACI)Laurent Gbagbo, président du Parti des Peuples Africains - Côte d'Ivoire (PPA... - KOACI l'Info au Coeur de l'Afrique
IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET platform, targeting CD20 developed for the treatment of B-cell non-Hodgkin's lymphomas
SAR'579/IPH6101, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46×CD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, now under development by
Results support further investigation of two new ProTriTAC™ protease-activated T cell engager development candidates, with demonstrated therapeutic potential in a broad range of TROP2- and... | April 17, 2023
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Data from T cell Engager Portfolio for Hematologic Malignancies, Including First... | November 3, 2022
STOCKHOLM, Sept. 7, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq: ONCO) (Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological
IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Innate's
- Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer -
Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option